# Study to Evaluate the Efficacy and Safety of Sirolimus in Subjects With Metastatic, Mismatch Repair Deficient Solid Tumors After Immunotherapy

> **NCT04393454** · PHASE2 · TERMINATED · sponsor: **Albert Einstein College of Medicine** · enrollment: 6 (actual)

## Conditions studied

- Metastatic dMMR Solid Cancer
- Solid Tumor
- Cancer
- Metastatic Solid Tumor

## Interventions

- **DRUG:** Sirolimus 2mg Tablet

## Key facts

- **NCT ID:** NCT04393454
- **Lead sponsor:** Albert Einstein College of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-11-16
- **Primary completion:** 2023-05-16
- **Final completion:** 2023-05-16
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** Following discussion with the Cancer Center the PI elected to terminate the study.
- **Last updated:** 2024-07-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04393454

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04393454, "Study to Evaluate the Efficacy and Safety of Sirolimus in Subjects With Metastatic, Mismatch Repair Deficient Solid Tumors After Immunotherapy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04393454. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*